logo-loader

Constellation Healthcare’s true valuation closer to US$400mln, says boss

Published: 15:38 11 Feb 2016 GMT

Paul Parmar, chief executive of Constellation Healthcare Technologies (LON:CHT), says that his company is undervalued and he is a “definite buyer” of the shares at the current price.

He attributes general market volatility to the suppression of the stock and says the true valuation of the company, which provides billing services to doctors in the U.S., is closer to US$400mln than today’s market cap of US$188mln.

Parmar spoke to Proactive after confirming the company’s fourth acquisition since Constellation listed on AIM in December 2014.  An upfront payment of US$28mln has been made for MDRX Medical Billing which could rise to US$30mln depending on MDRX's performance over the next two years.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

1 hour, 36 minutes ago